-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 UseyHc7uemqz8LlrTF15swvDAbLLMOBJgfgChFVCx0JXhzlWrwzmq9wVNl8t33dc
 AR+bXMDiDtpAcE4eRp7wiQ==

<SEC-DOCUMENT>0001144204-06-043591.txt : 20061025
<SEC-HEADER>0001144204-06-043591.hdr.sgml : 20061025
<ACCEPTANCE-DATETIME>20061025161959
ACCESSION NUMBER:		0001144204-06-043591
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20061025
FILED AS OF DATE:		20061025
DATE AS OF CHANGE:		20061025

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			XTL BIOPHARMACEUTICALS LTD
		CENTRAL INDEX KEY:			0001023549
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51310
		FILM NUMBER:		061163104

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3

	MAIL ADDRESS:	
		STREET 1:		KIRYAT WEIZMANN BUILDING 3
		CITY:			REHOVOT76100 ISRAEL
		STATE:			L3
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v055581_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff">
    <div>&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
    </div>
    <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UNITED
      STATES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Form
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Report
      of Foreign Private Issuer</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Pursuant
      to Rule 13a-16 or 15d-16</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>of
      the Securities Exchange Act of 1934</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      October 25, 2006</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission
      File Number: </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>000-51310</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>XTL
      Biopharmaceuticals Ltd.</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant's name into English)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>750
      Lexington Avenue, 20</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup><strong>th</strong></sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      Floor</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><u>New
      York, New York 10022</u></strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form 20-F or Form 40-F.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      40-F
<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1): <font face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7): <font face="Wingdings">o</font></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether by furnishing the information contained in this Form,
      the
      registrant is also thereby furnishing the information to the Commission pursuant
      to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
<font face="Wingdings">o</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
&#8220;Yes&#8221;
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): 82-</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      N/A
</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div>
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><img src="xtlbio.jpg" alt="xtlbio logo"></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>XTL
      BIOPHARMACEUTICALS LTD. AGM POSTPONED UNTIL NOVEMBER 1,
      2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NEW
      YORK, NEW YORK,</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>October
      25</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>
      2006</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      - XTL
      Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announces
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">today
      that its Annual General Meeting (&#8220;AGM&#8221;) was postponed for one week in accordance
      with its articles of association due to the absence of a quorum. The postponed
      AGM will take place at </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Company, Building 3, Kiryat Weizmann Science Park, Rehovot, PO Box 370, Israel
      76100 at 4:00 p.m. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">on
      November 1, 2006. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Any
      proxy
      votes received at any time up to 48 hours prior to the postponed AGM will be
      included in the total votes counted for the AGM. Those shareholders who have
      a
      valid &#8220;proof of ownership&#8221; in Israel or a letter of representation from
      Computershare, the Company&#8217;s registrars, and attend the meeting in person will
      also be permitted to vote.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>ABOUT
      XTL BIOPHARMACEUTICALS LTD.</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">XTL
      Biopharmaceuticals Ltd. (&#8220;XTL&#8221;) is engaged in the acquisition, development and
      commercialization of therapeutics for the treatment of infectious diseases,
      with
      a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule,
      non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is
      currently in a Phase 1 clinical trial in patients with chronic hepatitis C.
      XTL
      is also developing XTL-6865 - a combination of two monoclonal antibodies against
      the hepatitis C virus - presently in Phase 1 clinical trials in patients with
      chronic hepatitis C. XTL&#8217;s hepatitis C pipeline also includes several families
      of pre-clinical hepatitis C small molecule inhibitors. &#160;XTL also has an
      active in-licensing and acquisition program designed to identify and acquire
      additional drug candidates. XTL is publicly traded on the NASDAQ, London, and
      Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div><br>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; WIDTH: 100%; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURES</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, as amended, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><strong>XTL
              BIOPHARMACEUTICALS LTD.</strong></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:
              October 25, 2006</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/
              Bill
              Kessler<font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt" size="3">&#160;</font></font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <div>
                <hr style="COLOR: black" align="left" noshade size="2" width="80%">
              </div>
              <div><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Bill
                Kessler</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;</font></div>
              <div><font size="2">Director of Finance</font></div>
            </td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>

      </table>
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>xtlbio.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 xtlbio.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`!6`/D#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MKS[XH^/9_"-C;6FF-#_:=WN.74/Y,8!&_&>&W$;<@@[6STK2E2E5FH1W9,YJ
M$>9GH-%?,&E?%#Q;I>H2W9U1[P3,6D@N_GC)YZ#C8,G.$*C@=ABOI+2-5M=;
MTBTU.S?=;W,8D3)!*YZJ<$C<#D$9X((K?%8.IA[.6J9G2KQJ[%VBBBN0V"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"N(^(WB3Q%X3T^'5-*@L;BRW".X6>&1GC8YPV58#:>!SC!(Z[N.WJ&\M(+^
MQN+.Z3S+>XC:*5,D;E88(R.1P>U:4IQA-.2NB9IN-D['@?\`PO3Q/_SXZ1_W
MYE_^.5/XBCG^*?AJU\0Z58[M;T_-MJ%I$X):/!=70%L[<[L#!8EB.=N3PGBO
MPW=>$_$-QI-TWF>7AHI@A42H>0PS^1QD`@C)Q6O\-O%R^$?%"S74CKIMROE7
M04%MHZJ^T'DJ>^"=I;`R:^BE0A&'ML.M5JO/R/+523ER57H8NE>%]<UO4);#
M3]+N9KF%BDRE-@B89X<M@(?E(Y(Y&.M>T>*?$J_"GPOHFA:.+:XO0N6$ZDKL
MY+N5#[E+.21U'##M7I=Y=P6%C<7ET_EV]O&TLKX)VJHR3@<G@=J^3_%?B2Z\
M6>(;C5KI?+\S"Q0ARPB0<!1G\SC`)).!FN:C4ECYKG5H1_%FLXK#Q]UZL[3_
M`(7IXG_Y\=(_[\R__'*ZZ_\`B'XGTWX:V/B2ZLM.2[O;T1Q1&*4*("C$,06S
MN)3(()!4@]Z\T^&WA%?%WBA8;J-VTVV7S;HJ2NX=%3<!P6/;(.T-@Y%>W?$G
MPG?^,?#MOI^GRVT4T=VLY:X9E7:$=>P/.6%3B5AJ=:-/E2[E4G5E!ROZ'EW_
M``O3Q/\`\^.D?]^9?_CE'_"]/$__`#XZ1_WYE_\`CE'_``HOQ/\`\_VD?]_I
M?_C=5=2^#/B+2]+N]0GO=+:&U@>=U260L552QQE!S@5NE@&[*QG_`+2NY:_X
M7IXG_P"?'2/^_,O_`,<H_P"%Z>)_^?'2/^_,O_QRO,:['PG\-M8\8Z7+J&GW
M-C%#'.8"MQ(ZMN"JW93QAA6U3#86FN:<4D9QJUI.T6;O_"]/$_\`SXZ1_P!^
M9?\`XY1_PO3Q/_SXZ1_WYE_^.4?\*+\3_P#/]I'_`'^E_P#C=<=XL\)W_@[5
M(M/U"6VEFD@$X:W9F7:69>X'.5-9TZ>"J/E@DV5*6(BKRN>@Z#\9O$6J>(M,
MT^>RTM8;J[B@=DBD#!6<*<9<\X->Y5\D^#_^1VT#_L(V_P#Z,6OK:O.S.C"E
M.*@K'5A)RG%\S"BBBO,.LY;Q+XEO-&U&.WMXH&1H0Y,BDG))'8CTK8T._EU/
M1X+R94623=D("!PQ'?Z5QWCO_D.0_P#7LO\`Z$U=1X2_Y%BS_P"!_P#H;5Z=
M>C".#A-+5_\`!/GL%BJT\UJT92O%)V7S1M4445YA]"%8WB75I]&TZ.XMTC9V
MF"$2`D8()[$>E;-4-6TF#6;5;>X>145PX,9`.0".X/K6M!P51.IL<V,C5E0E
M&B[2MH9OA?7KK6_M?VF.%/)V;?+!&<[LYR3Z5T-9>CZ#:Z)YWV:29_.V[O,(
M.,9QC`'K6I58F5.55NDO=(P$*\,/&.(=YZW^]V_`****P.P****`"BBB@`HH
MHH`\^^*_@W_A(_#QO[&T\W5K+#)Y:9DEB_BCZC.,[AU.00!EC7SA7VA7S3\5
M/"">%O$HFM!C3]0WS0J%51&V?GC`'\(RI'`X8#G!->WE6)_Y<R^7^1P8RE]M
M?,9J7Q$N=0^&]EX6,3B:)A'/.=NV2!,&-0,<$';D_P#3,<G<<<7##+<3QP01
MO+-(P1(T4LS,3@``=233*]E^"?A**5Y/%%T4=HF,-FJ3`E&P0[.HZ'#``$]"
M3CE37H594\)2E)+_`(=G-!2K329Z7X+\+P>$?#4&FQ_-.?WMTX<L'F(`8C('
MR\`#@<`9YR:Z"BBOEIS<Y.4MV>O&*BK(*Q?&'_(DZ_\`]@ZX_P#1;5M5B^,/
M^1)U_P#[!UQ_Z+:G2^->HI_"SY)KZ"^!?_(DWO\`V$7_`/1<=?/M?07P+_Y$
MF]_["+_^BXZ^BS3_`'=^J/,PG\0].KY]^.G_`".UE_V#D_\`1DE?05?/OQT_
MY':R_P"P<G_HR2O+RO\`WA>C.S%_PSB_!_\`R.V@?]A&W_\`1BU];5\D^#_^
M1VT#_L(V_P#Z,6OK:MLW^./H9X+X6%%%%>0=IY[X[_Y#D/\`U[+_`.A-5VQ\
M10:-X3M(P/,O&5VCC(.,&1QN)].#QU_G5+QW_P`AR'_KV7_T)JB\'Z/#J=_+
M-<J'AMP#Y9/WF/3([C@_IU&:^@Y*;P<)5=EKZGPSJ5XYM5AA_BG=7?39M_*Q
M2N_$NKWC[FO9(P"2%A.P#/;CD_CFK>G^,=2LHDBDV7*!LEI22^.XW9_F#_2O
M1T18T5$4*B@!548`'H*YWQ-X?L[G3KF]AA2*ZC4R%U^4,!DMD#J2,\]<XYK"
MGC,/4:ISIV7]>AW5LJQ^'B\12KN4DM;W_P`W<W+*^MM1MQ<6DPEC)(R,C!'8
M@\BL[Q+JT^C:='<6Z1L[3!")`2,$$]B/2N-\'7S6NO1Q>8%BN`4<,<`G&5_'
M/`^I]:Z/QW_R`X?^OE?_`$%JQ>$C2Q<:;U3.J.:3Q.65*\?=G'33OIL3^%]>
MNM;^U_:8X4\G9M\L$9SNSG)/I6]--%;Q-+-(D<:]7=@`/Q-<;\/_`/F(_P#;
M+_V:HO&^K,]PNF0N1&@#3`<;F/(!X[#!].?:BKA%4QCI0T6GY(,/F;HY5'$U
MGS2=UZN[M_79#=6\;W#SR1:8$2$<+,RY<G/)`/`!]Q^7;*;6M?4KJ+7-T(W.
M%<K^Z)P1@#&WL>W:NA\(>'HEMTU.[B#2.0\"L#\@&?F]#GJ..P(KL*UJ8G#X
M>7LZ=-.V[9S4,OQV.@J]>LXWU273L]U_GYG$:/XW*A8=54MS_P`?"`=SW4>G
M/(]N*[*VN8;NW2XMY!)$XRK#O7(^,/#R[&U2SB._.;A$'!']_P#Q_/U)J^"M
M8FCO1IDC%H)`QC&,[&`R?H"`?Q_&IK8>E6HNO05K;HTPN.Q.$Q:P6,?,G\,N
M_;_+O<[VBBBO)/I@HHHH`9--%;P23SR)%#&I=Y'8*JJ!DDD]`!7R_P#$3Q>_
MB_Q*\T9QI]KNAM%#-AER?WA!QAFX/0<!0<XS7HOQF\:M:0#PQI\SI/,H>\DC
M<<1D'$1[@MP3T^7'4,:\0AAEN)XX((WEFD8(D:*69F)P``.I)KWLLPO+'VTM
MWMZ'G8NM=\B&5W7PK\7IX6\2F&[.-/U#9#,Q95$;9^20D_PC+`\CAB><`5UW
MB3X50:5\,%>%(9-9T_==7-Q&"/.7^-<L1\JK@CCG8<`%S7B]=L9TL73E%;;?
M\$P<9T9)O<^T**\^^%'C+_A(_#PL+Z[\W5K+*OYCYDEB_ADZ#.,[3U.0"3EA
M7H-?,5:4J4W"6Z/6A-3BI(*Q?&'_`").O_\`8.N/_1;5M5B^,/\`D2=?_P"P
M=<?^BVI4OC7J$_A9\DU]!?`O_D2;W_L(O_Z+CKY]KZ"^!?\`R)-[_P!A%_\`
MT7'7T6:?[N_5'F83^(>G5\^_'3_D=K+_`+!R?^C)*^@J^??CI_R.UE_V#D_]
M&25Y>5_[PO1G9B_X9Q?@_P#Y';0/^PC;_P#HQ:^MJ^2?!_\`R.V@?]A&W_\`
M1BU];5MF_P`<?0SP7PL****\@[3SWQW_`,AR'_KV7_T)JZ/P9`L/AR)U))F=
MW;/8YV\?@HKG/'?_`"'(?^O9?_0FKI/!TT<GAN!$;+1,Z.,=#N)_D17L8B_U
M"%O+]3Y3`<O]M5K]G;\#>HHIKNL:,[L%102S,<`#U->.?5MV/'["=;74;6X<
M$I%,CL%ZD`@\5W7CO_D!P_\`7RO_`*"U<9HB-)KM@$4L1<(<`9X#`D_D,UV?
MCO\`Y`</_7RO_H+5]%BFOK=)'P>6I_V9B7TT*7P__P"8C_VR_P#9JY*_G6ZU
M&ZN$!"2S.ZANH!)/-=;\/_\`F(_]LO\`V:N4U*U^PZG<VH#A8I&5=XY*YX/X
MC!K2C;ZW5[Z?D88M2_LO#VVO+[[NWZGKL,,=O!'#$NV.-0BC.<`#`I]16TZW
M5K#<("$E174-U`(SS4M?-.]]=S]!ARN*Y=B*Y@6ZM9K=R0DJ,C%>H!&.*\IT
M1VCUVP*,5)N$&0<<%@"/R.*]4O+C[)8W%SMW^3&TFW.,X&<9KRW089)]?L$C
M7<PG5R,XX4Y/Z`UZ^6_PJE]O^`SY;B"SQ.'4?BO^JM^IZS1117CGU85S_C3Q
M1!X1\-3ZE)\TY_=6J%"P>8@E0<$?+P2>1P#CG`KH*\^\<?#6Z\:ZO'=RZ_\`
M9;>&,1PVPM2X7NS$^8!N)[@#@*.V:VPZINHO:NR,ZCDH^XM3YVO+N>_OKB\N
MG\RXN)&EE?`&YF.2<#@<GM7JOP8\&_;+Y_$>HVFZV@^6R\U.'ESS(O/\&,#@
MC)X.5J[_`,*!_P"IF_\`)#_[97K>D:5:Z)I%IIEFFVWMHQ&F0`6QU8X`&XG)
M)QR237K8W'TW2Y*+W_(XZ&&DI\TT7:^8/B3X17PCXH:&UC==-N5\VU+$MM'1
MDW$<E3VR3M*Y.37T_7,>./!=KXUTB.TEG^RW$,@DAN1$'*]F4C@[2.P(Y"GM
MBN#`XGV%6\MGN=.(I>TAIN?.'A3Q)=>$_$-OJUJOF>7E982Y42H>"IQ^8SD`
M@'!Q7UA9W<%_8V]Y:OYEO<1K+$^"-RL,@X/(X/>O'?\`A0/_`%,W_DA_]LKT
M'P/X5NO!^D2:9+JO]H6_F&2',)C,6?O*/G8;<\X`')8\YXZ,PJX>LE.G+WEY
M,RPT*E/W9+0Z>L7QA_R).O\`_8.N/_1;5M52UC3_`.UM$O\`3?-\K[7;20>9
MMW;-ZE<XR,XSTS7FP:4DV=<E=-'QY7T%\"_^1)O?^PB__HN.L7_A0/\`U,W_
M`)(?_;*]!\"^$/\`A"M$FTW[=]L\VY:?S/)\O&55<8W'^[USWKV<?C*-6CRP
ME=_,X,/0J0G>2.GKY]^.G_([67_8.3_T9)7T%7GWCKX8?\)KK<.I?VQ]C\JV
M6#R_LWF9PS-G.\?WNF.U<&`JPI5N:;LCIQ$)3A:)\[6=W/87UO>6K^7<6\BR
MQ/@':RG(.#P>1WKKO^%L^-_^@W_Y*P__`!%=I_PH'_J9O_)#_P"V4?\`"@?^
MIF_\D/\`[97KSQF"GK-I^J?^1PQH5X[:?,XO_A;/C?\`Z#?_`)*P_P#Q%'_"
MV?&__0;_`/)6'_XBNT_X4#_U,W_DA_\`;*/^%`_]3-_Y(?\`VRH^L9?V7_@/
M_`*]GB?/[_\`@F5H?B'5?$MD]YJ]U]IN$D,2OY:IA0`0,*`.K'\ZZ_PUKRZ)
M<3>=$9()@-Q3[RD9QC/!ZG_/6;0_A1_8MD]M_;7G;I#)N^R[<9`&,;SZ5TK^
M#[2;2+>SEE)G@#!+A%P3DDX(YR,GIG\1DT5<9A)0]GNGV35CY]Y7F"QDL335
MFM4VUKTMOU5S436]*D17&HVH#`$;I5!_$$Y%<SXF\51O$UCILJ2+(K)/)MR,
M=,*>_&><'J,&JLW@._65A#=6SQ]F?<I/X`'^=7=/\"1HR2:A<^9CDQ1#`SG^
M\>2,>PZ]:Y:<,%2?M'/F\CKKULWQ4705+DON[_K?\KE#P1IK3ZDU^V1';@A3
M_><C&.G.`3GZBMGQW_R`X?\`KY7_`-!:NF1%C1410J*`%51@`>@K-U[1_P"V
M[%+;S_)VR"3=LW9P",8R/6L/K:J8J-6>B1V?V6Z&6SPU+WI/Y79SWP__`.8C
M_P!LO_9J=XXTE=B:I$#OR(Y0J\$<X8G\AS[?CL^'_#_]A?:/]*\_SMO_`"SV
MXQGW/K6U15Q:CBW6IZK\]!8;+'4RR.$KJTM?.SNVGH_U.`\+^*(]/B%C?'%L
M,F.4+DH>I!`Z@G_..G9?VSI?_02L_P#O^O\`C6'J/@>TNK@S6MP;7<26CV;E
M'^Z,C'?UZ]JQO^$$U3_GO9_]]M_\36]2.#Q$O:<W*WNCCH3S;`P]BZ?.EL[]
M/ZVN@\4^)5U+_0[)\V@VLS[2I=N>/]WIU'45;\$:.&+:K,I^4E(.2.V&;WZX
M'XUHZ;X*L;1_,NG-VX.5#+M0=.HR<]^IQSTKIJBOBZ4*7L,/MU9M@\KQ%7%?
M7,;:ZV6]NWW=-PHHHKRSZ,****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
FBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
